Background
==========

Potassium disorders occur frequently in hospitalized patients \[[@B1],[@B2]\] and it has long been known that extreme potassium values can cause life-threatening complications, especially in critically ill patients \[[@B3],[@B4]\]. However, the effects on outcome of less pronounced differences in the potassium concentration, that occur much more frequently, are not known.

As is the case with most laboratory parameters, plasma potassium values are considered as \"normal\" when they equal those observed in a healthy reference population. Although desirable levels for some laboratory parameters in critically patients may equal healthy reference levels, for others, such as hemoglobin, albumin or calcium, this is not the case \[[@B5]-[@B7]\]. Although potassium is administered to the majority of intensive care unit (ICU) patients, the optimal level in critically ill patients has never been investigated. There are no prospective trials concerning potassium regulation and only a few observational studies and reviews that describe the treatment once severe potassium disorders have developed \[[@B3],[@B8],[@B9]\]. Potassium has recently been involved in the debate on the disparate results of the Leuven \[[@B10]\] and NICE-SUGAR \[[@B11]\] trials that both compared glucose control targets, since the outcome of tight glucose control might be affected by potentially insufficiently controlled potassium levels \[[@B12]\].

Potassium regulation in the critically ill patient can be performed by titrated continuous potassium infusion. To avoid hyper- and hypokalemia, regular plasma potassium measurements and subsequent adjustments of the infusion rate are necessary \[[@B13]-[@B16]\]. To achieve two target values within a narrow range an effective potassium regulation protocol is mandatory. For safety and efficiency, computerized protocols appear to be superior over paper protocols \[[@B17]-[@B19]\]. In our ICU we have implemented an integrated computer-assisted program for both glucose and potassium regulation that is called GRIP-II (Glucose and potassium Regulation for Intensive care Patients) \[[@B20]-[@B22]\]. This program provides a recommendation on the potassium and insulin infusion rates and the time to the next potassium and glucose measurement. These recommendations are mainly based on the current potassium and glucose levels and analysis of their trend over time. In a before-after study comparing GRIP-II potassium control with physician-driven potassium control, potassium control improved with a significantly reduced number of hypokalemic and hyperkalemic events \[[@B20]\]. In the latter study the GRIP-II program aimed for a potassium level in the middle of the normal range of 3.5-5.0 mmol/L, i.e 4.3 mmol/L. However, it is not known what the effects would be when the target would be slightly different, i.e in normal-low or normal-high target range.

Potassium is the main intracellular cation of the body. The intracellular to extracellular potassium ratio affects both the fluid balance and the resting membrane potential. The reference plasma potassium ranges from 3.5 to 5.0 mmol/L. Levels below 3.0 mmol/L or above 6.0 mmol/L can cause serious symptoms of which cardiac arrhythmias are the most frequently observed \[[@B4]\]. After cardiac surgery (especially valvular surgery) postoperative atrial fibrillation is one of the most common complications with a reported incidence of 10-50%. It is associated with adverse outcome and despite new treatment strategies the incidence remains high \[[@B23]-[@B26]\]. After a potassium load, the intracellular compartment acts as the primary buffer. A potassium shift from extracellular to intracellular is caused by increased activity of the Na-K-ATPase pump, which can be directly stimulated by an increase in plasma potassium, insulin, catecholamines, aldosterone and alkalosis \[[@B27]-[@B29]\]. The most important organs in the homeostasis of potassium are the kidneys as they normally excrete or reabsorb potassium according to the overall potassium balance \[[@B30]\]. There is some evidence that a normal-high plasma potassium level is preferable in several cardiovascular states \[[@B31]-[@B33]\]. However, the optimal potassium level in the critically ill patient, who may be especially prone to the adverse effect of potassium derangements, has never been investigated prospectively. A cautious approach towards finding best target levels for potassium seems justified given the problematic discussions over optimal glucose targets in ICU patients \[[@B10],[@B12]\]. A computer-assisted potassium regulation program such as GRIP-II provides the opportunity to perform a clinical trial to safely and efficiently compare two potassium targets within the normal range.

In this prospective phase 4 trial we will compare the effect of two different potassium control-target values that are both within the reference range of 3.5 - 5.0 mmol/L. In the NLP (Normal-Low Potassium) trial arm a normal-low potassium level of 4.0 mmol/L is aimed for, while in the NHP (Normal-High Potassium) trial arm a normal-high potassium level of 4.5 mmol/L is aimed for. We hypothesize that both physiological and pathophysiological differences may exist between the normal-low and the normal-high potassium control targets. In the study all patients are allocated to either the 4.0 or 4.5 mmol/L control target in alternating blocks of patients.

The GRIP-COMPASS trial thus constitutes a novel trial in a number of aspects. It is the first clinical trial to assess the effect of different potassium target levels. Also it is the first trial to compare two control-targets that are both within the reference range in critically ill patients. Furthermore this trial compares two treatment strategies that both are executed by a computer-based potassium suppletion algorithm.

Methods/Design
==============

The GRIP-COMPASS trial is a single-center, prospective trial with alternating blocks of patients with blinded evaluation of the primary endpoint. Twelve hundred patients are assigned to the NLP control-target of 4.0 mmol/L or the NHP control-target of 4.5 mmol/L at ICU admission (Figure [1](#F1){ref-type="fig"}). Allocation to an arm is alternated in blocks of approximately 50 patients until 1200 patients are included, resulting in 24 blocks (Figure [2](#F2){ref-type="fig"}). Informed consent for inclusion into one of the two study arms was waived by our institutional review board since in both the NLP arm and the NHP arm standard potassium treatment is involved with the only difference that the two therapeutic strategies aim at differing normal levels.

![**The GRIP-COMPASS flow-chart**. ICU, intensive care unit; GRIP II, glucose and potassium regulation for intensive care patients.](1471-2253-10-23-1){#F1}

![**Planned patient allocation scheme**. To create two comparable groups while reducing bias from various time-dependent system effects the GRIP computer is instructed to regularly alternate between the targets of 4.0 and 4.5 mmol/L. The goal is to include 50 patients in each block, where the precise timing of a block change may also depend on logistic factors.](1471-2253-10-23-2){#F2}

The study will be performed in a 14-bed thoracic-ICU (closed-format) of a tertiary university teaching hospital. The institutional medical ethics committee of the University Medical Center of Groningen approved the study (METc 2009/096). The trial protocol has been registered at ClinicalTrials.gov (NCT 01085071).

Inclusion
---------

All patients admitted to the thoracic ICU are considered eligible for inclusion. Excluded are those patients who do not have a central venous catheter or an enteral feeding tube because such patients are not entered into the GRIP-II program for potassium regulation since they cannot receive continuous potassium administration to the extent that is regularly necessary. Only rarely will patients be excluded for this reason. Immediately after admission a patient is assigned a potassium control-target that remains unchanged for that patient until discharge to the general ward. The general characteristics of the population admitted to the thoracic ICU are summarized in table [1](#T1){ref-type="table"}. The majority of patients (\~75%) are admitted after cardiac surgery, i.e. coronary artery bypass surgery (CABG) and/or valve repair.

###### 

General characteristics of expected patient cohort.

                              Thoracic ICU
  --------------------------- --------------
  Age (years), median (IQR)   66 (57-74)
  Male sex                    69%
  APACHE II, median (IQR)     14 (10-18)
  Reason for admission        
   Cardiac surgery            75%
   Cardiac arrest             9%
   Other surgery              10%
   Medical                    5%
   Miscellaneous              3%
  post-operative AFF\*        50%
  In-hospital mortality       8%

\*after cardiac surgery

Baseline characteristics of a recent cohort of 500 patients that were admitted to the thoracic ICU, to provide an impression of the expected patient population in the GRIP-COMPASS trial. The incidence of AFF was observed in a subgroup of 150 consecutive cardiac surgery patients. Abbreviations used in table: ICU intensive care unit; IQR interquartile range; APACHE II acute physiology and chronic health evaluation II score; AFF atrial fibrillation and atrial flutter.

Potassium regulation
--------------------

Potassium will be regulated by the computer-assisted decision support system called GRIP-II. This nurse-centered system for both potassium and glucose control was implemented at our ICU in 2004 to improve safety and efficiency. It is, to our knowledge, the first computer-assisted protocol for both glucose and potassium regulation. Both the design and results of both the glucose and potassium algorithm in a large and diverse cohort of ICU patients have been published previously \[[@B20]-[@B22]\]. GRIP-II provides a recommendation for the potassium and insulin infusion rate based the patients\' potassium and glucose levels and the trend over time. It also gives an advice on the time-interval to the next potassium (and glucose) measurement and monitors if this measurement is performed on time. The average required number of point-of-care measurements per patient per day is 5.6, which is low compared to other computer-assisted glucose protocols \[[@B34],[@B35]\].

Depending on the assigned group (NLP or NHP) GRIP-II will aim for a potassium control-target of 4.0 mmol/L or 4.5 mmol/L. The glucose target ranges are the same for both groups (4.0-7.5 mmol/L). Given the proximity of the targets of the NLP-arm and the NHP-arm that both lie comfortably within the reference range and since the spread in potassium levels actually achieved by GRIP-II was sufficiently small (median 4.3 with an interquartile range of 4.1-4.5 mmol/L) potassium levels for both trial arms are expected to stay within the reference range as well as would be the case without GRIP-II.

Both potassium and glucose are measured in arterial blood samples of 0.5 ml lithium-heparin anticoagulated blood using the ABL-800 series point-of-care analyser (Radiometer Copenhagen, Denmark) that is present on in the ICU. Potassium chloride is administered continuously by syringe pump either parenterally by central venous catheter or enterally. To minimize dosing errors it is administered in a \"one-to-one\" 1 mmol/ml solution. Potassium chloride suppletion in critically ill patients is efficient and safe in a dose-dependent and predictable way (independent of the use of diuretics or the kidney function) \[[@B15],[@B16],[@B36]\]. The maximum administration rate advised by GRIP-II is 20 mmol/hour. When a higher infusion rate is required, the attending physician can decide to administer more than 20 mmol/hour. Magnesium is supplemented at 30 mmol/day in patients after cardiac surgery \[[@B9]\]. In non-cardiac surgery patients, magnesium is only suppleted when total magnesium levels are \<0.80 mmol/L.

Primary endpoint
----------------

The primary endpoint is the incidence of in-hospital atrial fibrillation or atrial flutter (denoted by AFF), confirmed by a 12-lead electrocardiogram (ECG), in patients after cardiac surgery. The reference period over which this primary endpoint is determined is the first 7 days post-surgery, or until hospital discharge if the patient is discharged earlier. The presence of AFF is established by evaluation of all electrocardiograms by independent and qualified cardiologists who are blinded to the treatment allocations.

Secondary endpoints
-------------------

Secondary endpoints include:

\- AFF that develops more than 7 days post-surgery and until hospital discharge.

\- AFF in patients who do not undergo cardiac surgery during ICU stay, the first week after ICU discharge, until hospital discharge.

\- The time course of the incidence of AFF (in cardiac-surgery patients and total patient group).

\- The incidence of other serious arrhythmias that require immediate medical intervention (in cardiac-surgery patients and total patient group).

\- Time that potassium is in the 3.5-5.0 mmol/L reference range during ICU-admission (in cardiac-surgery patients and total patient group).

\- The occurrence of distinct hypokalemia (i.e potassium \<2.8 mmol/L) and distinct hyperkalemia (i.e. potassium \>6.0 mmol/L) in cardiac-surgery patients and the total patient group, also a safety endpoint.

\- Level of glucose control and insulin requirements during ICU admission.

\- Biochemical disturbances of electrolytes (sodium, magnesium and calcium), blood gas analysis, lactate and renal function (creatinine, urea) during hospital admission (total patient group).

\- Cumulative fluid balance during ICU admission (patients admitted to the ICU for more than 5 days).

\- ICU and hospital length of stay (in cardiac-surgery patients and total patient group).

\- ICU-mortality and hospital mortality (in cardiac-surgery patients and total patient group, also a safety endpoint) as well as 90-day, and 1 year mortality.

In addition to the cardiac surgery group and the total patient group, the following subgroups will also be compared:

\- Patients who underwent CABG with the use of cardiopulmonary bypass versus patients who underwent CABG without cardiopulmonary bypass.

\- Patients with a history of AFF prior to surgery versus patients without a history of AFF prior to surgery.

Data collection
---------------

Baseline patient characteristics are collected at ICU admission (age, sex, length, weight, medical history, medication use, reason of admission). If a patient undergoes (cardiac) surgery, data concerning the procedure and the duration of the procedure (and the time on cardiopulmonary bypass) are collected. For cardiac surgery patients the EuroSCORE model for operative risk stratification is calculated \[[@B37]\]. In non-cardiac surgery patients the APACHE II score is used \[[@B38]\].

This trial requires no specific tests or procedures that are not regularly performed. Daily laboratory tests and blood gas analysis (daily at the ICU, in the general ward only when deemed necessary by the physician) are all part of standard care. During ICU admission all patients are under continuous rhythm monitoring (3-lead) and a 12-lead ECG is done at admission (in cardiac-surgery patients also after 24 and 48 hours), and is repeated when arrhythmias or other complications occur or are suspected. At the general ward a the rhythm is checked regularly and a 12-lead ECG is performed at admission, when deemed necessary by the attending physician, and at discharge. When a patient is prone for severe arrhythmias, continuous monitoring by telemetry is continued at the general ward. All in-hospital ECGs of the included patients are evaluated by the physicians at the ICU and the general ward as well as by independent cardiologists who are blinded for the potassium control-targets.

Potassium and glucose control data (potassium and glucose levels, amount of potassium chloride and insulin administration, number of measurements per day) are automatically stored by the GRIP-II program. All other laboratory tests are stored in the hospital information system. ICU-parameters such as the amount of fluid administered, the use of vasoactive drugs, anti-arrhythmic drugs, diuresis, and the fluid balance are monitored and collected. Minor complications and major complications (e.g. death, stroke, myocardial infarction, organ failure and major bleeding complications) are recorded. Mortality is recorded for the ICU, during hospitalisation and at 90-days. Follow-up information will be obtained from hospital records and the central personal records database.

Sample size calculation
-----------------------

Because the incidence of AFF in patients after cardiac surgery is the primary endpoint, the incidence recently measured in these patients and the expected potential difference in this incidence between the NLP and NHP groups were the main determinants of the power analysis. In a pilot study of 150 consecutive patients admitted after open-heart surgery (CABG and/or valve replacement) during a 3-month period, we observed that 50% developed postoperative AFF at the ICU or at the ward. To detect a 10% reduction in the incidence of AFF, with a two-sided level of significance of 5% and a power of 80%, 2 × 400 cardiac surgery patients should be included. Assuming that approximately 75% of the admitted patients will undergo cardiac surgery and with a 10% margin for excluded patients we arrived at a target number of 1200 consecutive patients admitted to the ICU to be included.

In a previous analysis of potassium regulation with GRIP-II, patients reached a stable potassium level within 12 hours with a mean ± standard deviation (SD) level of 4.25 ± 0.36 mmol/L \[[@B20]\]. When we assume that GRIP-II maintains this level of accuracy, then a significant difference in plasma potassium between the NLP and NHP groups will be found with less than 50 patients. Thus we do expect to easily detect very significant differences in the potassium levels between the NLP and NHP groups.

Statistical analysis
--------------------

To compare groups, the Student\'s t test (normally distributed variables), the Mann-Whitney U test (other continuous variables) or Fisher\'s exact test (categorical variables) will be used when appropriate. The level of potassium control will be expressed as the time within the normokalemic range (3.5 - 5.0 mmol/L) divided by the total time spent on the ICU.

In multivariate analysis we will investigate the interaction with glucose, the amount of administered insulin, sodium and magnesium. A two-sided P value of \<0.05 will be considered significant. The Statistical package for the social sciences (SPSS) version 16.0 will be used for all statistical analysis.

Conclusion
==========

The GRIP-COMPASS trial is a single-center, prospective, controlled trial with an alternating patient design to compare the effect of two different potassium control-targets that are both within the normal range in 1200 ICU patients. A validated computer-assisted potassium regulation algorithm has an indispensable role in carrying out this large trial. The primary outcome measure will be the incidence of atrial fibrillation and flutter in patients after cardiac surgery.
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